Giovanni Di Liberto, MD-PhD
banner
dilibertomd.bsky.social
Giovanni Di Liberto, MD-PhD
@dilibertomd.bsky.social
Neurologist / Scientist investigating the pathobiological mechanisms in Autoimmune Neurology
Reposted by Giovanni Di Liberto, MD-PhD
Reposted by Giovanni Di Liberto, MD-PhD
Lipid metabolism and neuroinflammation: What is the link? rupress.org/jem/article/...
August 6, 2025 at 1:40 PM
Our new paper is finally out! A terrific joint effort to advance our understanding of T cell mediated neurodegeneration in AE !

“Neuronal pSTAT1 hallmarks synaptic pathology in autoimmune encephalitis against intracellular antigens”

link.springer.com/article/10.1...
April 28, 2025 at 4:30 PM
Reposted by Giovanni Di Liberto, MD-PhD
Divergent sex-specific pannexin-1 mechanisms in microglia and T cells underlie neuropathic pain: Neuron www.cell.com/neuron/fullt...
Divergent sex-specific pannexin-1 mechanisms in microglia and T cells underlie neuropathic pain
Panx1 channels mediate sex-specific immune mechanisms in neuropathic pain: leptin from CD8+ T cells drives pain in females, while VEGF from microglia mediates pain in males. Panx1-targeted therapies o...
www.cell.com
January 31, 2025 at 4:50 PM
Reposted by Giovanni Di Liberto, MD-PhD
Reposted by Giovanni Di Liberto, MD-PhD
Pour l'année 2024, la Commission de la #Recherche de la
@fbm-unil.bsky.social (CRFBM) a mis au concours différents types de #financement en #médecine de #précision.

💸 Découvrez les #récipiendaires des 5 projets retenus!
www.unil.ch/news/1733846...
January 10, 2025 at 8:08 AM
Maudes et al. present a new mouse model of anti-NMDAR encephalitis, which provides a platform for studying the underlying disease mechanisms and allows testing of treatments over an extended disease course. tinyurl.com/muc9f8fx
Neuro-immunobiology and treatment assessment in a mouse model of anti-NMDAR encephalitis
Maudes et al. have developed a mouse model of anti-NMDAR encephalitis, an autoimmune disease mediated by autoantibodies against the GluN1 subunit of the NM
tinyurl.com
January 3, 2025 at 8:03 AM